Targets › NMDAR
2 programs from 2 companies in 3 trials: 3 Phase 4; Other, Genitourinary; next expected readout Jan 2027.
Open in Phaseline: the race on NMDAR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rawalpindi Institute of Cardiology | Ketamine-Propofol NMDA receptor antagonist combined with GABA-A agonist | NMDAR, GABRA1 | Phase 4 | Propofol | Jan 2027 |
| Peking University First Hospital | Intranasal dexmedetomidine-esketamine Combination of alpha-2 adrenergic agonist and NMDA receptor antagonist | ADRA2A, NMDAR, ADRA2B, ADRA2C, GRIN1 | Phase 4 | Adenotonsillectomy; General Anesthesia | Feb 2027 |
Propofol (1) Adenotonsillectomy (1) General Anesthesia (1)
small molecule (2)
Rawalpindi Institute of Cardiology (1) Peking University First Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.